Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Articles published by Pheast Therapeutics
Pheast Therapeutics to Present Initial Phase 1a Clinical Data and Two New Preclinical Studies of PHST001, a Novel Anti-CD24 Antibody, at AACR 2026
Today 16:30 EDT
From
Pheast Therapeutics
Via
Business Wire
Pheast Therapeutics Receives FDA Fast Track Designation for PHST001 for the Treatment of Ovarian Cancer
June 03, 2025
From
Pheast Therapeutics
Via
Business Wire
Pheast Therapeutics Announces First Patient Treated in Phase 1 Clinical Trial of PHST001 for Patients with Advanced Solid Tumors
April 14, 2025
From
Pheast Therapeutics
Via
Business Wire
Pheast Appoints Dr. Raphaël Rousseau as Chief Medical Officer
February 18, 2025
From
Pheast Therapeutics
Via
Business Wire
Pheast Presents New Preclinical Data for PHST001, an Anti-CD24 Macrophage Checkpoint Inhibitor, at SITC 2024
November 07, 2024
From
Pheast Therapeutics
Via
Business Wire
Pheast Unveils First Preclinical Data for PHST001, an Anti-CD24 Macrophage Checkpoint Inhibitor
May 13, 2024
From
Pheast Therapeutics
Via
Business Wire
Pheast Appoints Jacopo Leonardi as Chief Executive Officer
January 05, 2023
From
Pheast Therapeutics
Via
Business Wire
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.